EIN PRESSWIRE

Lung Injury Market Size to Reach $2.4 Billion & Growing at 4.20% CAGR by 2030

Lung Injury Market

Lung Injury Market

Rise in awareness related to treatment of ALI or acute respiratory distress syndrome (ARDS) is anticipated to augment the growth of the lung injury market

PORTLAND, OR, UNITED STATES, September 22, 2021 /EINPresswire.com/ — Lung injury is commonly characterized by hypoxia, lung complication, and pulmonary edema. This condition causes inflammation or direct injury to the lungs. Symptoms include severe shortness of breath, low blood pressure, confusion and extreme tiredness. Acute lung injury (ALI) is a multi-factorial process, the onset of which is triggered by environmental factors among genetically predisposed individuals. Although ALI-inducing events are common, only a fraction of those exposed develop the syndrome.

Lung Injury Market by Application, Technology, and end user: global opportunity analysis and industry forecast, 2021–2030,” the global lung injury market size was valued at $1.5 billion in 2020 and is projected to reach $2.4 billion by 2030 registering a CAGR of 4.20% from 2021 to 2030.

Download Free Sample Report@ https://www.alliedmarketresearch.com/request-sample/13445

Lung Injury Market Report provides an overview of the market based on key parameters such as market size, sales, sales analysis and key drivers. The market size of the market is expected to grow on a large scale during the forecast period (2019-2026). This report covers the impact of the latest COVID-19 on the market. The coronavirus epidemic (COVID-19) has affected all aspects of life around the world. This has changed some of the market situation. The main purpose of the research report is to provide users with a broad view of the market. Initial and future assessments of rapidly.

Lung Injury Market Competitive Analysis:-

Apeptico Forschung Und Entwicklung GmBH, Bayer AG, General Electric Company, Glaxosmithkline Plc, Koninklijke Philips N.V., Linde Plc., Medtronic Plc., Ony Biotech Inc, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Provided in this report. These players have adopted various strategies including expansions, mergers & acquisitions, joint ventures, new product launches, and collaborations to gain a strong position in the industry.

Rise in prevalence of lung-related diseases and increase in geriatric population act as the key driving forces of the global lung injury market. Furthermore, rise in awareness related to treatment of ALI or acute respiratory distress syndrome (ARDS) is anticipated to augment the growth of the global lung injury market. However, complications associated with the use of therapies and low adoption rate due to these complications act as the major deterrents of the market. Conversely, pipeline drugs for ALI, which are in the last of clinical trial, are expected to offer potential growth opportunities for the market during the forecast period.

The global lung injury market is segmented into therapy, end user, and region. Depending on therapy, the market is bifurcated into medication and device. The medication segment is further categorized into pharmacotherapy, fluid management, and inhaled nitric oxide. Moreover, the devices is subdivided into mechanical ventilation and adjunctive procedures devices.

On the basis of injury type, the market is classified into direct injury and indirect injury. By end user, it is fragmented into hospitals & clinics, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

On the basis of therapy, the medication segment was the major shareholder 2020, as various therapies were used as supportive treatment for lung injury.

Depending on injury type, the direct injury acquired the largest share in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to rise in incidence of pulmonary infections worldwide.

Inquiry for Buying @ https://www.alliedmarketresearch.com/purchase-enquiry/13445

Asia-Pacific accounted for the largest share of the global lung injury market in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to the presence of large population base, increase in awareness associated with lung injury treatment, and rise in healthcare expenditure. Furthermore, surge in incidence of pulmonary infections in the region, which require the use of medications and devices for treatment of lung injury drives the growth of the market in this region.

Trending Reports of Healthcare:

Monoclonal Antibody Market – Global Opportunity Analysis and Industry Forecast, 2019-2028

Dental Adhesives Market – Global Opportunity Analysis and Industry Forecast, 2019-2028

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Analytics LLP
503-894-6022
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Lung Injury Market Size to Reach $2.4 Billion & Growing at 4.20% CAGR by 2030 1